Com.l.it DX® Breast (solid or liquid )
The Com.pl.i.t DX® Liquid Breast test is specifically intended for postmenopausal women diagnosed with ER+ and HER2- breast cancer. This test is an effective instrument for evaluating breast cancer status and can inform the decision regarding the necessity of specific targeted therapies for a patient.
The Com.pl.i.t DX® Liquid Breast Test is ap
- Patients with inoperable malignancies and those with insufficient or inadequate tissue biopsy samples Individuals having numerous metastases.
- Patients undergoing therapy or following the conclusion of treatment. This indicates the potential appearance of novel targetable mutations or mutations that provide resistance to the employed therapy.
The test is strongly endorsed for precise treatment determinations for:
Postmenopausal women with advanced or metastatic ER+/HER2- breast cancer who have relapsed after previous therapy will be evaluated for treatment with Elacestrant, contingent upon the presence of ESR1 gene mutations.
Postmenopausal women with advanced or metastatic ER+/HER2- breast cancer who have relapsed after previous therapy will be evaluated for treatment with Alpelisib, contingent upon the presence of PIK3CA gene alterations.
Postmenopausal women with advanced or metastatic breast cancer have relapse following previous therapy, necessitating decisions on off-label or clinical trial treatments.
The Com.pl.i.t DX Liquid Breast test:
- Identifies the molecular profile of the tumor, including gene mutations and copy number variations, for inoperable cancers.
- Identifies the approved medication that targets the mutant gene(s) or the associated pathway of the gene(s).
- Identifies mutations linked to resistance against targeted therapy.
- Advocates for off-label treatments and/or identifies remedies presently undergoing clinical trials.
Genetic Mutations
Hotspot genes (about 152 hotspots):AKT1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, KRAS, PIK3CA, SF3B1, TPS3
BRCA1, BRCA2, RB1, PTEN, PALB2, NF1, COK4, CDK4, CCND1, CATA3, FDFR1, FGFR2
Copy Number Variation (CNV)
Copy number variations (CNVs): CCND1, ERBB2, FGFR1
Complete genes TP53
The gene panel indicates mutations in the ESR1 gene, with a prevalence of 48% as a mechanism of resistance to hormone therapy, according to the Emerald study
We also identify PIK3CA mutations with the approved therapy Alpelisib, along with other genes for which experimental or off-label therapies exist.
| 23 Genes with SNV/Indels Analyzed | ||||||||
|---|---|---|---|---|---|---|---|---|
| AKT1 | BRCA1* | BRCA2* | CDH1 | CDK4* | CDK6* | CCND1* | EGFR* | ERBB2* (HER2) |
| ERBB3 | ESR1 | FBXW7 | FGFR1 | FGFR2* | FGFR3* | GATA3 | KRAS* | NF1 |
| PALB2* | PIK3CA* | PTEN* | RB1* | TP53* | ||||
Copy number variations (CNVs): CCND1, ERBB2, FGFR1 Complete genes TP53 The gene panel indicates mutations in the ESR1 gene, with a prevalence of 48% as a mechanism of resistance to hormone therapy, according to the Emerald study We also identify PIK3CA mutations with the approved therapy Alpelisib, along with other genes for which experimental or off-label therapies exist. | ||||||||
| 7 Gene Fusions | ||||||||
| FGFR1 | FGFR2 | FGFR3 | NTRK1 | NTRK2 | NTRK3 | RET | ||
| MSI | ||||||||
Sample Results Report
Addresses recurrent or metastatic breast carcinoma Estrogen Receptor Positive / Human Epidermal Growth Factor Receptor 2 Negative
Blood in a specialized STRECK vial provided by Scipharm. Blood in a specialized collection vial that you will retrieve from Scipharm. Cell-Free DNA BCT® (10 ml) and Cell-Free RNA BCT® (10 ml).
Scipharm is tasked with supplying and dispatching the specialized vial for the Com.Pl.i.t DX® Liquid Breast test. Kindly reach out to us.
Scipharm is accountable for the requisite processes concerning the acquisition and return of your sample.
Your results will be transmitted to your physician through a secure network and to you via email, accompanied by a secure unique code issued by customer service.
Results will be accessible within 10 business days following the receipt of your sample.
The Customer Service Department will issue a distinct e-banking payment code, or payment may be executed Via bank transfer.
Our Customer Service Team is dedicated to addressing your inquiries concerning the services provided by Scipharm. For inquiries regarding the ordering of tests, please reach out to us directly.
To finalize the test, you must complete and submit the Consent form available at the link below.
